Eikon Therapeutics filed SEC paperwork signaling intent to pursue a public listing on Nasdaq to fund advancement of its clinical-stage oncology pipeline. The company—backed by more than $1.1 billion in private funding—cited priorities including late-stage trials for TLR7/8 co-agonist EIK1001 (Phase III for melanoma and Phase II/III for NSCLC) and PARP1 inhibitor programs. Eikon’s IPO plans follow heavy private investment rounds and position the company to access public capital for pivotal trials and expansion of clinical programs. The filing underscores investor appetite for platform-enabled drug-discovery firms and could presage a pickup in biopharma listings if market conditions remain favorable.